COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Clinical Trials

Please Contact Dr. Theodore Friedmann with questions regarding this list: 858-534-4268.


Principal InvestigatorDisease TargetStudy Name
Adams S. FleisherAlzheimer's DiseaseA Phase I Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-based, Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects with Mild to Moderate Alzheimer’s Disease 
Bary Greenberg Cardiac DiseasePhase I Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID Trial)
Ehtisham MahmudAngina Pectoris AWARE: Angiogenesis in Women with Angina Pectoris Who Are Not Candidates for Revascularization Cardium Therapeutics Protocol No. CT-3-001
Frederick E. MillardRenal AdenocarcinomaAn International, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate whether TroVax®, Added to First-Line Standard Of Care Therapy, Prolongs the Survival of Patients with Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma (Protocol No. TV3/001/06)
Gerit D MulderDiabetic UlcersA Long-Term (Year 15) Follow-Up Study of Subjects who were Previously Enrolled in Tissue Repair Company-Sponsored Clinical Trials Using GAM501. (Formerly: A Dose Escalating Phase 1 Study of AdPDGF-B/Collagen (GAM501) in the Treatment of Diabetic Ulcers of the Lower Extremity.)
Gregory A Daniels Metastatic MelanomaA Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma Sponsor [Protocol LX01- 315] 
Gregory A Daniels MelanomaA Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects with Stage III Melanoma
Gregory A DanielsMelanomaA Phase I, Open Label, Dose-Escalation Study of Intratumoral Injection of Adenovirus-Cd154 (Ad-ISF35) in Patients with Unresectable Melanoma or Squamous Cell Carcinoma
H Kirk Hammond  Adenyl cyclase type Vl
Januario CastroLymphocytic LeukemiaA Phase Ib/Ii Study of Repeat Intranodal Injections of Adenovirus-Cd154 (Ad-Isf35) in Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Januario Castro Lymphocytic LeukemiaA Phase Ib Study of Repeated Doses of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Combination with Fludarabine, Cyclophosphamide and Rituximab (FCR) in Subjects with Chronic Lymphocytic Leukemia (CLL) 
Lyudmila A. BazhenovaLung CancerPhase III Prospective, Randomized, Double-blind, Registration Study of Lucanix™ (belagenpumatucel-L) vs. Best Supportive Care as Frontline, Adjuvant Therapy for Stages III/IV Non-small Cell Lung Cancer (Protocol No: NR001-03)
Robert Weisman Squamous Cell CarcinomaA Phase III, Multi-Center, Open Label, Randomized, Study to Compare the Overall Survival and Safety of Bi-Weekly Intra-Tumoral Administration of INGN 201 (Ad5CMV-p53) Versus Weekly Methotrexate in 240 Patients with Refractory Squamous Cell Carcinoma
Susan J. LittleHIV-1 VaccineA Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Antiretroviral Effect of Immunization with the MRK Ad5 Hiv-1 Gag Vaccine in Hiv-1 Infected Individuals Who Interrupt Antiretroviral Drug Therapy
Susan J. LittleHIV-1 VaccineACTG A5187. A Phase I/II Clinical Trial to Evaluate the Safety and Immuno-Genicity of the HIV-1 DNA Vaccine VRC-HIVDNAA009-00VP (Gag-Pol-Nef-Multiclade Env) in HIV-1 Infected Subjects Treated during Accute Infection [Version 1.0]
Susan J. LittleHIV-1AIN504/ACTGA5218: A Randomized Study of Therapeutic Immunization and Treatment Interruption among Subjects Who Began Potent Antiretroviral Therapy Within 16 Days of Diagnosis of Acute or Recent HIV Infection.
Tony R ReidEsophageal CancerGV-001.005: Phase II, Multi-Center, Single Arm Evaluation of Preoperative Chemoradiation Plus TNFerade Biologic (ADgvEGR.TNF.11D) Prior to Esophagectomy for Locally Advanced Resectable Esophageal Cancer.
Tony R Reid Colorectal AdenocarcinomaCT 1030: A Phase I/II, Open-Label Study (with a Sequential Dose Escalation Stage Followed by an Expansion of a Selected Dose Cohort), to Evaluate the Safety and Anti-Tumor Effects of NV1020, Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-Line Chemotherapy, in Patients with Colorectal Adenocarcinoma Metastic to the Liver.
Tony R ReidMelanomaOncoVEXGM-CSF/002/03: A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX GM-CSF in Patients with Inoperable Malignant Melanoma.
Tony R ReidMelanomaA Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus plus GM-CSF) Administered by Intratumoral Injection in Patients with Unresectable Stage 3 or Stage 4Malignant Melanoma (Protocol No. JX594-IT-MEL005)
Tony R ReidHepatocellular CarcinomaA Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus plus GM-CSF) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma (Protocol No.: JX594-IT-HEP007)
Tony R ReidPancreatic CancerGV - 001.004: A Randomized, Phase II/III, Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. 
Tony R ReidPancreatic CancerA Phase 2 Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-Resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations.